189 related articles for article (PubMed ID: 6233399)
1. High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia.
Hines JD; Oken MM; Mazza JJ; Keller AM; Streeter RR; Glick JH
J Clin Oncol; 1984 Jun; 2(6):545-9. PubMed ID: 6233399
[TBL] [Abstract][Full Text] [Related]
2. 4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia.
Kahn SB; Sklaroff R; Lebedda J; Conroy JF; Bulova S; Brodsky I
Am J Clin Oncol; 1983 Aug; 6(4):493-502. PubMed ID: 6191561
[TBL] [Abstract][Full Text] [Related]
3. [Combination of AMSA-high dose cytosine arabinoside in acute leukemia].
Zittoun R; Rio B; Marie JP; Blanc CM
Presse Med; 1985 Jun; 14(26):1417-20. PubMed ID: 3161047
[TBL] [Abstract][Full Text] [Related]
4. Intermediate-dose cytosine arabinoside and amsacrine. An effective regimen with low toxicity in refractory acute nonlymphocytic leukemia.
Dekker AW; Nieuwenhuis HK; Verdonck LF
Cancer; 1990 May; 65(9):1891-4. PubMed ID: 2372760
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
Tallman MS; Appelbaum FR; Amos D; Goldberg RS; Livingston RB; Mortimer J; Weiden PL; Thomas ED
J Clin Oncol; 1987 Jun; 5(6):918-26. PubMed ID: 3585446
[TBL] [Abstract][Full Text] [Related]
6. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
Jehn U; Heinemann V; Wilmanns W
Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
[TBL] [Abstract][Full Text] [Related]
7. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia.
Herzig RH; Lazarus HM; Wolff SN; Phillips GL; Herzig GP
J Clin Oncol; 1985 Jul; 3(7):992-7. PubMed ID: 3894588
[TBL] [Abstract][Full Text] [Related]
8. Intermediate and high-dose ARA-C and m-AMSA (or daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukaemia and lymphoblastic non-Hodgkin lymphoma.
Willemze R; Peters WG; van Hennik MB; Fibbe WE; Kootte AM; van Berkel M; Lie R; Rodenburg CJ; Veltkamp JJ
Scand J Haematol; 1985 Jan; 34(1):83-7. PubMed ID: 3855571
[TBL] [Abstract][Full Text] [Related]
9. High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase I Pilot Study for the Eastern Cooperative Oncology Group.
Hines JD; Mazza JJ; Oken MM; Bennett JM; Adelstein DJ; Keller A; O'Connell MJ
Semin Oncol; 1985 Jun; 12(2 Suppl 3):117-9. PubMed ID: 3839318
[No Abstract] [Full Text] [Related]
10. Results of induction and consolidation treatment with intermediate and high-dose cytosine arabinoside and m-Amsa of patients with poor-risk acute myelogenous leukaemia.
Peters WG; Willemze R; Colly LP
Eur J Haematol; 1988 Mar; 40(3):198-204. PubMed ID: 3162718
[TBL] [Abstract][Full Text] [Related]
11. Treatment of acute leukemia with amsacrine and high-dose cytarabine.
Arlin ZA; Gaddipati J; Ahmed T; Mittelman A; Friedland M; Rieber E
Cancer Treat Rep; 1985 Sep; 69(9):1001-2. PubMed ID: 3839713
[TBL] [Abstract][Full Text] [Related]
12. Treatment of acute leukemia in relapse with 4'(9-acridinylamino) methanesulfon-m-anisidide (AMSA) in combination with cytosine arabinoside and thioguanine.
Arlin ZA; Flomenberg N; Gee TS; Kempin SJ; Dellaquila C; Mertelsmann R; Straus DJ; Young CW; Clarkson BD
Cancer Clin Trials; 1981; 4(3):317-21. PubMed ID: 6895190
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia.
Tschopp L; von Fliedner VE; Sauter C; Maurice P; Gratwohl A; Fopp M; Cavalli F
J Clin Oncol; 1986 Mar; 4(3):318-24. PubMed ID: 3456425
[TBL] [Abstract][Full Text] [Related]
14. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update.
Wolff SN; Herzig RH; Phillips GL; Lazarus HM; Greer JP; Stein RS; Ray WA; Herzig GP
Semin Oncol; 1987 Jun; 14(2 Suppl 1):12-7. PubMed ID: 3589687
[TBL] [Abstract][Full Text] [Related]
15. Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia.
Cassileth PA; Begg CB; Silber R; Spiers A; Burkart PT; Scharfman W; Knospe WH; Bennett JM; Mazza JJ; Oken MM
Cancer Treat Rep; 1987 Feb; 71(2):137-40. PubMed ID: 3802110
[TBL] [Abstract][Full Text] [Related]
16. High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study.
Cassileth PA; Lyman GH; Bennett JM; Glick JH; Oken MM
Am J Clin Oncol; 1984 Aug; 7(4):361-3. PubMed ID: 6547566
[TBL] [Abstract][Full Text] [Related]
17. Amsacrine [4'-(9-acridinylamino)-methanesulfon-m-anisidide] (m-AMSA) and 5-azacytidine (AZA) for remission reinduction in patients with relapsed adult acute nonlymphocytic leukemia. An ECOG pilot study. Eastern Cooperative Oncology Group.
Kahn SB; Spiers A; Knospe WH; Soojian M; Glick JH
Am J Clin Oncol; 1987 Feb; 10(1):78-81. PubMed ID: 2435142
[TBL] [Abstract][Full Text] [Related]
18. [Value of high-dose cytosine-arabinoside in the treatment of resistant acute leukemia].
Witz F; Olive D; Lederlin P; Bordigoni P; Troussard X; Grosbois B; Schaison G; Cornu G
Presse Med; 1987 Feb; 16(4):159-62. PubMed ID: 2950446
[TBL] [Abstract][Full Text] [Related]
19. [Mitoxantrone and conventional-dose cytosine arabinoside for relapsed and refractory acute leukemia].
Wakita A; Murase T; Uchida T; Fujiwara Y; Tanaka M; Ohkita T
Gan To Kagaku Ryoho; 1992 May; 19(5):653-7. PubMed ID: 1580638
[TBL] [Abstract][Full Text] [Related]
20. Acridinyl anisidide (m-AMSA) therapy in 11 patients with refractory acute leukemia.
Naparstek E; Shinar E; Polliack A
Isr J Med Sci; 1984 Feb; 20(2):118-22. PubMed ID: 6546740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
